Breaking Down Hubei Xingfa Chemicals Group Co., Ltd. Financial Health: Key Insights for Investors

Hubei Xingfa Chemicals' latest financial snapshot packs a mix of reassuring growth and cautionary signals: Q1 2025 sales rose to CNY 7.23 billion (up 4.94% year‑over‑year) while trailing twelve‑month revenue reached CNY 30.13 billion (up 6.49% YoY) against a 2024 annual revenue of CNY 28.40 billion; profitability shows a net profit margin of 10.03% in Q1 2025 (down from 11.68% a year earlier) with a TTM ROE of 7.50% and a gross margin of 17.77%, operational liquidity flags include a current ratio of 0.66 and a quick ratio of 0.31 even as operating cash flow TTM stands at CNY 1.73 billion and total cash was CNY 1.58 billion on March 31, 2025; leverage sits at a debt‑to‑equity ratio of 0.66, valuation metrics show a trailing P/E of 15.64 and a forward P/E of 10.53 with a P/S of 1.25 and P/B of 1.05, and growth drivers include Phase II capacity expansion, international bases in Indonesia and Ghana, and R&D spending of CNY 1.188 billion-read on to unpack what these figures mean for investors.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Revenue Analysis

• Q1 2025 sales: CNY 7.23 billion (up 4.94% vs. CNY 6.89 billion in Q1 2024)
• TTM revenue (as of 30 Sep 2025): CNY 30.13 billion (YoY +6.49%)
• Annual revenue 2024: CNY 28.40 billion (up 0.41% vs. 2023)
• Revenue per employee: ~CNY 2.13 million (14,121 employees)
• Price-to-sales (P/S) ratio: 1.25

• Growth pattern: gradual, consistent increases year-over-year with Q1 and TTM improvements indicating momentum acceleration into 2025.
• Efficiency signal: revenue per employee (~CNY 2.13M) suggests moderate operational productivity relative to peers in chemical manufacturing.
• Valuation context: P/S of 1.25 implies the market values roughly 1.25x the company's annual sales, a useful benchmark against sector peers.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Profitability Metrics

Key profitability indicators for Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) show mixed signals: while EPS improved year-over-year in Q3 2025, margins have compressed on a quarterly and trailing basis, suggesting margin pressure despite absolute profit growth in some periods. Relevant metrics are presented below for investor assessment and comparative context.

• The decline in net profit margin from 11.68% to 10.03% over the year likely reflects higher operational costs, input price pressures, or competitive pricing reducing markup.
• ROE at 7.50% indicates moderate effectiveness converting equity into net income; not high for capital-intensive chemical peers but positive given sector cyclicality.
• Operating margin (6.54%) is narrower than gross margin (17.77%), highlighting significant operating expenses (SG&A, R&D, logistics, energy) between gross profit and operating income.
• EPS improvement to CNY 0.53 in Q3 2025 shows earnings growth per share despite margin compression-potential drivers include higher volumes, one-off gains, or share count reductions.

For additional corporate background that contextualizes these profitability metrics within the company's strategy and business model, see: Hubei Xingfa Chemicals Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Debt vs. Equity Structure

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) displays a capital structure with moderate leverage and notable short-term liquidity pressures. Key ratio data point to how the company balances debt financing against equity and its ability to service obligations.

• Leverage profile: Debt-to-equity of 0.66 signals moderate reliance on external financing rather than aggressive gearing.
• Liquidity constraints: Current ratio 0.66 and quick ratio 0.31 both point to short-term liquidity stress - current liabilities materially exceed liquid assets.
• Interest burden: Interest coverage of 6.51 provides a buffer for interest payments, reducing immediate refinancing pressure despite low liquidity.

Investor implications:

• Operational resilience is required to convert working capital into cash quickly given the low current and quick ratios.
• Refinancing or maturity concentration risk should be monitored because total debt levels are not disclosed for 2025-03-31; ratio metrics must be used for assessment.
• Moderate debt leaves room for strategic financing but limits flexibility if cash flows deteriorate.

For context on corporate direction and governance that may influence capital allocation, see Mission Statement, Vision, & Core Values (2026) of Hubei Xingfa Chemicals Group Co., Ltd.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Liquidity and Solvency

• Current ratio: 0.66 - indicates potential difficulty meeting short-term obligations using current assets alone.
• Quick ratio: 0.31 - signals limited ability to cover immediate liabilities without selling inventory.
• Interest coverage ratio: 6.51 - reflects comfortable capacity to meet interest expense from operating income.
• Total cash (as of March 31, 2025): CNY 1.58 billion - a material liquidity buffer on the balance sheet.
• Operating cash flow (TTM): CNY 1.73 billion - supports ongoing operational liquidity and reduces reliance on external financing.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Valuation Analysis

• Trailing P/E: 15.64 - the market is paying 15.64 times the company's last twelve months (LTM) earnings.
• Forward P/E: 10.53 - implies expected earnings growth or improved profitability, and signals potential undervaluation relative to trailing earnings.
• Price-to-Book (P/B): 1.05 - market valuation is roughly at book value, indicating limited premium for intangible growth or exceptionally strong ROE.
• Enterprise Value / Revenue (EV/Revenue): 1.33 - market values the firm at 1.33x its revenue, a moderate top-line multiple for the chemicals sector.
• Enterprise Value / EBITDA (EV/EBITDA): 7.79 - suggests a reasonable enterprise-level valuation relative to operating cash earnings.

• Relative positioning: The forward P/E materially below the trailing P/E signals either consensus expected profit recovery or a market re-rating; comparing to peers and historical ranges is essential to confirm.
• Asset backing: P/B ≈1 implies limited market premium for intangible growth-useful when stress-testing downside scenarios and balance sheet resilience.
• Enterprise multiples: EV/Revenue of 1.33 and EV/EBITDA of 7.79 indicate the market prices both top-line and cash-operating performance conservatively, consistent with moderate growth expectations.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Risk Factors

• Net profit margin deterioration: reported net profit margin fell from 8.5% (prior year) to 4.2% (most recent year), signaling margin compression that may reflect higher input costs, weaker selling prices, or operational inefficiencies.
• Liquidity constraints: current ratio of 0.92 and quick ratio of 0.61 indicate short-term assets are insufficient to fully cover near-term liabilities without relying on inventory liquidation or new financing.
• Leverage and financial flexibility: debt-to-equity ratio at 0.66 represents a moderate leverage profile-manageable but limiting in periods of stress, potentially increasing borrowing costs or constraining capital spending.
• Input price exposure: dependence on phosphate and related chemical feedstocks exposes margins to raw material price swings and supply disruptions.
• Regulatory risk: tighter environmental and emissions standards in China and export markets can require capital expenditures and raise operating costs for chemical producers like Hubei Xingfa.
• Demand cyclicality: exposure to construction, agriculture (fertilizers) and industrial end-markets means revenue and profitability are vulnerable to economic slowdowns or reduced demand in key sectors and geographies.

• Operational cost pressure: rising energy, logistics and environmental compliance costs can further compress margins; margin sensitivity is higher when net profit margin is already reduced.
• Refinancing and interest-rate sensitivity: with moderate leverage, material increases in interest rates or tightening credit conditions could raise interest expense and reduce free cash flow.
• Inventory and working capital risk: low quick ratio implies reliance on inventory turnover and favorable receivables collection; any slowdown in sales or stretched receivables would worsen liquidity.
• Commodity price volatility scenario: a sustained 10-20% rise in key feedstock prices (e.g., phosphate rock, sulfur) could eliminate a large portion of current operating profit given thin margins.

• Regulatory and ESG-related capex: estimated compliance investments (e.g., emissions control, wastewater treatment) can be capital-intensive and may require multi-hundred-million-CNY outlays over medium term, impacting free cash flow and ROE.
• Market concentration risk: reliance on fertilizer and specialty chemical markets concentrates revenue exposure-any contraction in construction/agriculture demand will disproportionately affect top-line and margins.

Hubei Xingfa Chemicals Group Co., Ltd. (600141.SS) - Growth Opportunities

• Phase II expansion at the Hubei Xinxuanhong Production Plant slated to commence H2 2025, with partial production capacity expected online in 2026.
• International production bases in Indonesia and Ghana intended to broaden market access and reduce single‑market concentration.
• R&D investment elevated to CNY 1.188 billion, supporting formulation upgrades, process optimization and new product pipelines.
• Strategic focus on high‑value‑added products and strict quality control to drive margin expansion and market share gains in specialty chemicals.
• Supply chain strengthening and enhanced environmental protection initiatives aligned with ESG trends and regulatory requirements, potentially unlocking premium contracts and new customers.
• Sector tailwinds: recovery in the agrochemical market and improving specialty chemical demand create avenues for volume and price recovery.

• Execution milestones for Phase II (groundbreaking, equipment installation, first partial production in 2026).
• R&D outcomes: number of new products/commercialized formulations and contribution to gross margin.
• Revenue mix shift: domestic vs. international and commodity vs. specialty product proportions.
• Cost and working capital impacts from supply‑chain upgrades and environmental compliance investments.
• Market indicators: agrochemical price recovery, specialty chemical order book trends and regional demand in Southeast Asia and West Africa.